Immunomodulatory plasticity of mesenchymal stem cells and the strategy of clinical application

doi:10.16352/j.issn.1001-6325.2023.01.0002

Abstract

Abstract: Mesenchymal stem cells (MSCs) are pluripotent stem cells with self-renewal, multi-directional differentiation and immunoregulatory capabilities. More and more studies have demonstrated the beneficial role of MSCs in the treatment of immune disorders. However, there is heterogeneity in the immunoregulatory capacity of MSCs obtained in vivo or cultured in vitro, and the immunoregulatory capacity of MSCs is also regulated by the microenvironment. This review provides an overview of the mechanisms of the immunosuppressive and immune supportive abilities of MSCs, introduces recent studies on the immunoregulatory mechanisms of MSCs and the plasticity hypothesis of their immunoregulatory abilities, and discusses strategies to enhance the immunoregulatory abilities of MSCs in the cell production stage. This review aims to provide a reference for the clinical translational research of MSCs.

Key words: mesenchymal stem cells (MSCs), immunoregulation, immunomodulation plasticity

CLC Number:

WANG Haiyan, HAN Qin, ZHAO Chunhua. Immunomodulatory plasticity of mesenchymal stem cells and the strategy of clinical application[J]. Basic & Clinical Medicine, 2023, 43(1): 2-11.

References 65

[1]	Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement[J]. Cytotherapy, 2006, 8: 315-317.
[2]	Levy O, Kuai R, Siren EMJ, et al. Shattering barriers toward clinically meaningful MSC therapies[J]. Sci Adv, 2020, 6: 6884.
[3]	Renesme L, Pierro M, Cobey KD, et al. Definition and characteristics of mesenchymal stromal cells in preclinical and clinical studies: a scoping review[J]. Stem Cells Transl Med, 2022, 11: 44-54.
[4]	Madl CM, Heilshorn SC, Blau HM. Bioengineering strategies to accelerate stem cell therapeutics[J]. Nature, 2018, 557: 335-342.
[5]	Liu J, Li P, Zhu J, et al. Mesenchymal stem cell-mediated immunomodulation of recruited mononuclear phagocytes during acute lung injury: a high-dimensional analysis study[J]. Theranostics, 2021, 11: 2232-2246.
[6]	Zhu R, Yan T, Feng Y, et al. Mesenchymal stem cell treatment improves outcome of COVID-19 patients via multiple immunomodulatory mechanisms[J]. Cell Res, 2021, 31: 1244-1262.
[7]	Kosaric N, Srifa W, Bonham CA, et al. Macrophage subpopulation dynamics shift following intravenous infusion of mesenchymal stromal cells[J]. Mol Ther, 2020, 28: 2007-2022.
[8]	Moloudizargari M, Govahi A, Fallah M, et al. The mechanisms of cellular crosstalk between mesenchymal stem cells and natural killer cells: Therapeutic implications[J]. J Cell Physiol, 2021, 236: 2413-2429.
[9]	Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases[J]. Nat Rev Nephrol, 2018, 14: 493-507.
[10]	Jiang W, Xu J. Immune modulation by mesenchymal stem cells[J]. Cell Proliferation, 2020, 53: e12712.
[11]	Chen X, Liu Q, Huang W, et al. Stanniocalcin-2 contributes to mesenchymal stromal cells attenuating murine contact hypersensitivity mainly via reducing CD8(+) Tc1 cells[J]. Cell Death Dis, 2018, 9: 548.
[12]	Nikolic A, Simovic Markovic B, Gazdic M, et al. Intraperitoneal administration of mesenchymal stem cells ameliorates acute dextran sulfate sodium-induced colitis by suppressing dendritic cells[J]. Biomed Pharmacother, 2018, 100: 426-432.
[13]	Yao G, Qi J, Liang J, et al. Mesenchymal stem cell transplantation alleviates experimental Sjögren's syndrome through IFN-β/IL-27 signaling axis[J]. Theranostics, 2019, 9: 8253-8265.
[14]	Lai P, Weng J, Guo L, et al. Novel insights into MSC-EVs therapy for immune diseases[J]. Biomarker Res, 2019, 7: 6.
[15]	Nakazaki M, Morita T, Lankford K L, et al. Small extracellular vesicles released by infused mesenchymal stromal cells target M2 macrophages and promote TGF-β upregulation, microvascular stabilization and functional recovery in a rodent model of severe spinal cord injury[J]. J Extracell Vesicles, 2021, 10: e12137.
[16]	Bazzoni R, Takam Kamga P, Tanasi I, et al. Extra-cellular vesicle-dependent communication between mesenchymal stromal cells and immune effector cells[J]. Front Cell Dev Biol, 2020, 8: 596079.
[17]	Bulati M, Miceli V, Gallo A, et al. The immunomodula-tory properties of the human amnion-derived mesenchymal stromal/stem cells are induced by INF-γ produced by activated lymphomonocytes and are mediated by cell-to-cell contact and soluble factors[J]. Front Immunol, 2020, 11: 54.
[18]	Li C, Jin Y, Wei S, et al. Hippo signaling controls NLR family pyrin domain containing 3 activation and governs immunoregulation of mesenchymal stem cells in mouse liver injury[J]. Hepatology (Baltimore), 2019, 70: 1714-1731.
[19]	Sheng M, Lin Y, Xu D, et al. CD47-mediated hedgehog/SMO/GLI1 signaling promotes mesenchymal stem cell immunomodulation in mouse liver inflammation[J]. Hepatology (Baltimore), 2021, 74: 1560-1577.
[20]	Li Y, Zhang D, Xu L, et al. Cell-cell contact with proinflammatory macrophages enhances the immunotherapeutic effect of mesenchymal stem cells in two abortion models[J]. Cell Mol Immunol, 2019, 16: 908-920.
[21]	Zheng S, Huang K, Xia W, et al. Mesenchymal stromal cells rapidly suppress TCR signaling-mediated cytokine transcription in activated T cells through the ICAM-1/CD43 interaction[J]. Front Immunol, 2021, 12: 609544.
[22]	Corsello T, Amico G, Corrao S, et al. Wharton's jelly mesenchymal stromal cells from human umbilical cord: a close-up on immunomodulatory molecules featured in situ and in vitro[J]. Stem Cell Rev Rep, 2019, 15: 900-918.
[23]	Mittal SK, Cho W, Elbasiony E, et al. Mesenchymal stem cells augment regulatory T cell function via CD80-mediated interactions and promote allograft survival[J]. Am J Transpl, 2022, 22: 1564-1577.
[24]	Liu D, Gao Y, Liu J, et al. Intercellular mitochondrial transfer as a means of tissue revitalization[J]. Signal Transduct Target Ther, 2021, 6: 65.
[25]	Paliwal S, Chaudhuri R, Agrawal A, et al. Regenerative abilities of mesenchymal stem cells through mitochondrial transfer[J]. J Biomed Sci, 2018, 25: 31.
[26]	Morrison TJ, Jackson MV, Cunningham EK, et al. Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer[J]. Am J Respir Crit Care Med, 2017, 196: 1275-1286.
[27]	Luz-Crawford P, Hernandez J, Djouad F, et al. Mesenchymal stem cell repression of Th17 cells is triggered by mitochondrial transfer[J]. Stem Cell Res Ther, 2019, 10: 232.
[28]	Beier UH, Angelin A, Akimova T, et al. Essential role of mitochondrial energy metabolism in Foxp3+ T-regulatory cell function and allograft survival[J]. FASEB J, 2015, 29: 2315-2326.
[29]	Lu T, Zhang J, Cai J, et al. Extracellular vesicles derived from mesenchymal stromal cells as nanotherapeutics for liver ischaemia-reperfusion injury by transferring mitochondria to modulate the formation of neutrophil extracellular traps[J]. Biomaterials, 2022, 284: 121486.
[30]	Fu Y, Sui B, Xiang L, et al. Emerging understanding of apoptosis in mediating mesenchymal stem cell therapy[J]. Cell Death Dis, 2021, 12: 596.
[31]	Luk F, de White SFH,Korevaar SS, et al. Inactivated mesenchymal stem cells maintain immunomodulatory capacity[J]. Stem Cells Dev, 2016, 25: 1342-1354.
[32]	He X, Hong W, Yang J, et al. Spontaneous apoptosis of cells in therapeutic stem cell preparation exert immunomodulatory effects through release of phosphatidylserine[J]. Signal Transduct Target Ther, 2021, 6: 270.
[33]	Zheng C, Sui B, Zhang X, et al. Apoptotic vesicles restore liver macrophage homeostasis to counteract type 2 diabetes[J]. J Extracell Vesicles, 2021, 10: e12109.
[34]	Chow L, Johnson V, Impastato R, et al. Antibacterial activity of human mesenchymal stem cells mediated directly by constitutively secreted factors and indirectly by activation of innate immune effector cells[J]. Stem Cells Transl Med, 2020, 9: 235-249.
[35]	Normanton M, Alvarenga H, Hamerschlak N, et al. Interleukin 7 plays a role in T lymphocyte apoptosis inhibition driven by mesenchymal stem cell without favoring proliferation and cytokines secretion[J]. PLoS One, 2014, 9: e106673.
[36]	Xiong Y, Xiong Y, Zhang H, et al. hPMSCs-derived exosomal miRNA-21 protects against aging-related oxidative damage of CD4(+) T cells by targeting the PTEN/PI3K-Nrf2 axis[J]. Front Immunol, 2021, 12: 780897.
[37]	Bassani B, Tripodo C, Portararo P, et al. CD40 activity on mesenchymal cells negatively regulates OX40L to maintain bone marrow immune homeostasis under stress conditions[J]. Front Immunol, 2021, 12: 662048.
[38]	He Y, Qu Y, Meng B, et al. Mesenchymal stem cells empower T cells in the lymph nodes via MCP-1/PD-L1 axis[J]. Cell Death Dis, 2022, 13: 365.
[39]	Wang Y, Chen X, Cao W, et al. Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications[J]. Nat Immunol, 2014, 15: 1009-1016.
[40]	Waterman RS, Tomchuck SL, Henkle SL, et al. A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype[J]. PLoS One, 2010, 5: e10088.
[41]	Beldi G, Khosravi M, Abdelgawad ME, et al. TNFα/TNFR2 signaling pathway: an active immune checkpoint for mesenchymal stem cell immunoregulatory function[J]. Stem Cell Res Ther, 2020, 11: 281.
[42]	Zhang C, Zhou L, Wang Z, et al. Eradication of specific donor-dependent variations of mesenchymal stem cells in immunomodulation to enhance therapeutic values[J]. Cell Death Dis, 2021, 12: 357.
[43]	Mendt M, Daher M, Basar R, et al. Metabolic reprogramming of GMP grade cord tissue derived mesenchymal stem cells enhances their suppressive potential in GVHD[J]. Front Immunol, 2021, 12: 631353.
[44]	Yao M, Cui B, Zhang W, et al. Exosomal miR-21 secreted by IL-1β-primed-mesenchymal stem cells induces macrophage M2 polarization and ameliorates sepsis[J]. Life Sci, 2021, 264: 118658.
[45]	Deng L, Li H, Su X, et al. Chlorzoxazone, a small molecule drug, augments immunosuppressive capacity of mesenchymal stem cells via modulation of FOXO3 phosphorylation[J]. Cell Death Dis, 2020, 11: 158.
[46]	Liu Y, Yuan X, Muñoz N, et al. Commitment to aerobic glycolysis sustains immunosuppression of human mesenchymal stem cells[J]. Stem Cells Transl Med, 2019, 8: 93-106.
[47]	Killer MC, Nold P, Henkenius K, et al. Immunosuppressive capacity of mesenchymal stem cells correlates with metabolic activity and can be enhanced by valproic acid[J]. Stem Cell Res Ther, 2017, 8: 100.
[48]	Contreras-Lopez R, Elizondo-Vega R, Luque-Campos N, et al. The ATP synthase inhibition induces an AMPK-dependent glycolytic switch of mesenchymal stem cells that enhances their immunotherapeutic potential[J]. Theranostics, 2021, 11: 445-460.
[49]	Jitschin R, Böttcher M, Saul D, et al. Inflammation-induced glycolytic switch controls suppressivity of mesenchymal stem cells via STAT1 glycosylation[J]. Leukemia, 2019, 33: 1783-1796.
[50]	Planat-Benard V, Varin A, Casteilla L. MSCs and inflammatory cells crosstalk in regenerative medicine: concerted actions for optimized resolution driven by energy meta-bolism[J]. Front Immunol, 2021, 12: 626755.
[51]	Lim J, Heo J, Ju H, et al. Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway[J]. Sci Adv, 2020, 6: 1-18.
[52]	Gao L, Cen S, Wang P, et al. Autophagy improves the immunosuppression of CD4+ T cells by mesenchymal stem cells through transforming growth factor-β1[J]. Stem Cells Transl Med, 2016, 5: 1496-1505.
[53]	Dang S, Xu H, Xu C, et al. Autophagy regulates the therapeutic potential of mesenchymal stem cells in experimental autoimmune encephalomyelitis[J]. Autophagy, 2014, 10: 1301-1315.
[54]	Zhang J, Huang J, Gu Y, et al. Inflammation-induced inhibition of chaperone-mediated autophagy maintains the immunosuppressive function of murine mesenchymal stromal cells[J]. Cell Mol Immunol, 2021, 18: 1476-1488.
[55]	Wong SW, Lenzini S, Cooper MH, et al. Soft extracellular matrix enhances inflammatory activation of mesenchymal stromal cells to induce monocyte production and trafficking[J]. Sci Adv, 2020, 6: 1-13.
[56]	Regmi S, Seo Y, Ahn JS, et al. Heterospheroid forma-tion improves therapeutic efficacy of mesenchymal stem cells in murine colitis through immunomodulation and epithelial regeneration[J]. Biomaterials, 2021, 271: 120752.
[57]	Deng J, Li M, Meng F, et al. 3D spheroids of human placenta-derived mesenchymal stem cells attenuate spinal cord injury in mice[J]. Cell Death Dis, 2021, 12: 1096.
[58]	Olmedo-Moreno L, Aguilera Y, Baliña-Sánchez C, et al. Heterogeneity of in vitro expanded mesenchymal stromal cells and strategies to improve their therapeutic actions[J]. Pharmaceutics, 2022, 14: 1112.
[59]	Bowles AC, Kouroupis D, Willman MA, et al. Signature quality attributes of CD146(+) mesenchymal stem/stromal cells correlate with high therapeutic and secretory potency[J]. Stem Cells, 2020, 38: 1034-1049.
[60]	Zhang C, Han X, Liu J, et al. Single-cell transcriptomic analysis reveals the cellular heterogeneity of mesenchymal stem cells[J]. Genom Proteom Bioinform, 2022, 20: 70-86.
[61]	Xie Z, Yu W, Ye G, et al. Single-cell RNA sequencing analysis of human bone-marrow-derived mesenchymal stem cells and functional subpopulation identification[J]. Exp Mol Med, 2022, 54: 483-492.
[62]	Srinivasan A, Sathiyanathan P, Yin L, et al. Strategies to enhance immunomodulatory properties and reduce heterogeneity in mesenchymal stromal cells during ex vivo expansion[J]. Cytotherapy, 2022, 24: 456-472.
[63]	Tolomeo AM, Castagliuolo I, Piccoli M, et al. Extra-cellular vesicles secreted by mesenchymal stromal cells exert opposite effects to their cells of origin in murine sodium dextran sulfate-induced colitis[J]. Front Immunol, 2021, 12: 627605.
[64]	Gomzikova MO, James V, Rizvanov AA. Therapeutic application of mesenchymal stem cells derived extracellular vesicles for immunomodulation[J]. Front Immunol, 2019, 10: 2663.
[65]	Zhu Y, Ge J, Huang C, et al. Application of mesen-chymal stem cell therapy for aging frailty: from mechanisms to therapeutics[J]. Theranostics, 2021, 11: 5675-5685.